Clinical trial NCT06545175: Intracochlear Application of VSF1.01 for the Reduction of Cochlear Implant Surgery Related Trauma
Official title: Extracellular Vesicle-enriched Secretome Fraction (VSF1.01) for the Reduction of Cochlear Implant Surgery Related Trauma (ESCRT). an Open-label Monocentric Phase I/IIa Clinical Trial to Investigate the Safety of Intracochlear Application of VSF1.01 Enriched with HUC-MSC-EVs in Patients Receiving Cochlear Implantation.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Hearing Loss
Lead sponsor: Hannover Medical School
Sponsor class: OTHER
First posted: 2024-08-09
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to assess the safety of intracochlear application of VSF1.01 for the reduction of cochlear implant surgery related trauma in patients with profound hearing loss with or without non-functional residual hearing in low frequencies and cochlear implantation.

The main questions it aims to answer are:

Primary objective:

Safety of intracochlear application of VSF1.01 in patients receiving cochlear implantation

Secondary objectives:

Effectiveness on

1. neural responses of auditory nerve
2. speech understanding
3. hearing thresholds
4. electrode impedances

During cochlear implant operation, patients receive as adjuvant treatment intracochlear VSF1.01 prior to insertion of the electrode array.

Cochlear implantation is conducted according to the clinical standard at the investigational site.


Eligibility criteria: Inclusion Criteria:

* Men, women, inter/diverse aged ≥ 18 years

  * Women without childbearing potential defined as follows:

    * at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or
    * hysterectomy or uterine agenesis or
    * ≥ 50 years and in postmenopausal state \> 1 year or
  * Women of childbearing potential:

    * who are practicing sexual abstinence (periodic abstinence and withdrawal are not acceptable) or
    * who have sexual relationships with female partners only and/or with sterile male partners or
    * who are sexually active with fertile male partner, have a negative pregnancy test during screening and agree to use reliable methods of contraception from the time of screening until end of the clinical trial.
* Signed written informed consent from subjects capable of understanding all information and to give full informed consent
* Functional deaf patients (profound hearing loss with or without non-functional residual hearing in the low frequencies i.e. 125 Hz: 45 dB - 95 dB; 250 Hz: 50 dB - 105 dB; 500 Hz: 55 dB - 110 dB; 750 Hz and higher: 65 dB or below) that are candidates for cochlear implantation

Exclusion Criteria:

* Patients with prior ear surgery
* Patients with inner ear malformations
* Patients with acute or chronic otitis media
* Patients with keloid disorder
* Comorbidities concerning the central nervous system
* Malignancies of any type
* Kidney disease with elevated blood values: creatinine \>1.5x above upper limit of normal (ULN), eGFR or creatinine clearance 59 mL/min/1.73 m2 (grade ≥2, CTCAE v5.0)
* Liver disease with elevated blood values: bilirubin \>1.5x ULN, AST/ALT \>3.0x ULN, ALP and y-GT \>2.5x ULN, LDH \>ULN, international normalized ratio (INR) \>1.5-2.5x baseline if on anticoagulation, albumin \<3 g/dL (grade ≥2, CTCAE v5.0)
* Suspected or verified pregnancy or breastfeeding
* Hypersensitivity to any of the components of the medications used (such as Ringer's Lactate (excipient); any residuals from cell culture or raw materials used for pharmaceutical upstream and downstream processing to generate VSF1.01 (i.e. alpha-Modified Eagle Medium (αMEM), Dulbecco's MEM (DMEM), pooled human platelet lysate (pHPL), human serum albumin (HSA), Dipeptiven, phosphate buffered saline (PBS), animal origin free recombinant enzyme (TrypLETM Select))
* Participation in another clinical trial (other investigational drugs or devices at the time of enrolment or within 30 days prior to enrolment)

Primary outcomes:
measure: Rate and severity of (serious) adverse events
timeFrame: Continuously from start to end of study [Start: IMP treatment (day 0), end of the study (Follow-up 5)], assessed up to approximately 6 months
Secondary outcomes:
measure: Evaluation of eCAP growth function
timeFrame: Continuously from start to end of study [Start: IMP treatment (day 0), end of the study (Follow-up 5)], assessed up to approximately 6 months
measure: Evaluation of speech perception
timeFrame: From Day 1 (FU 1) to end of study (FU 5), assessed up to approximately 6 months
measure: Measurement of air and bone conduction
timeFrame: At Screening/baseline and from Day 1 (FU 1) to end of study (FU 5), assessed up to approximately 6 months
measure: Measurement of impedance levels
timeFrame: From Day 0 to end of study (FU 5), assessed up to approximately 6 months
Other outcomes:
Locations:
city: Hannover
country: Germany
facility: Hannover Medical School, Dept. of Otorhinolaryngology
Study officials:
affiliation: Hannover Medical School
name: Nils K. Prenzler, PD DR.
role: PRINCIPAL_INVESTIGATOR
References: